Company intelligence / Profile preview

Meep

Ownership: Private
Development stage: Other

Overview

Meep has developed a home-use minilab that enables rapid self-testing for up to 20 biomarkers simultaneously with accuracy comparable to clinical laboratory analyzers. The technology leverages silicon photonic biosensors and has been validated through European grants and collaborations with hospitals and large pharma companies. Initial applications include STD self-tests for chlamydia and gonorrhoea.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceDigital health platformDiagnostic test (Silicon photonics-based)
Industry: Molecular Diagnostics

Partnerships

Collaborations with hospitals and large pharmaceutical companies (names not specified)

Beyond the preview

Go deeper on Meep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meep.

Explore the full profile